Trial Profile
Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Irinotecan (Primary) ; Sunitinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jun 2012 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 04 Jan 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.